Opinion Article - Journal of Molecular Oncology Research (2024) Volume 8, Issue 4

Gene therapy in oncology: A revolutionary approach to cancer treatment

Seng Siow ^*

Department Of Oncology Research, Columbia University, USA

*Corresponding Author:

Seng Siow
Department Of Oncology Research, Columbia University, USA
E-mail:seng@siow.edu

Received: 01-July-2024, Manuscript No. AAMOR-24-149811; Editor assigned: 02-July-2024, PreQC No. AAMOR-24-149811(PQ); Reviewed:15-July-2024, QC No. AAMOR-24-149811; Revised:19-July-2024, Manuscript No. AAMOR -24-149811 (R); Published:26-Oct-2024, DOI:10.35841/ aaijrm -8.4.243

Citation: Siow S. Gene therapy in oncology: A revolutionary approach to cancer treatment. J Mol Oncol Res. 2024;8(4):243

Introduction

Oncology, the study and treatment of cancer, has witnessed significant advancements in recent years. One of the most promising developments is the application of gene therapy, a technique that involves altering genetic material within cells to combat or prevent disease. Cancer is a genetic disease at its core, characterized by mutations in the DNA that control cell growth and division. By targeting these mutations, gene therapy offers a potential solution to treat cancer at its root cause, rather than merely addressing its symptoms [1, 2].

Cancer arises due to specific genetic mutations that enable uncontrolled cell proliferation. Traditional treatments, such as chemotherapy and radiation, are often nonspecific, attacking both healthy and cancerous cells. Gene therapy, on the other hand, focuses on correcting or modifying the faulty genes responsible for cancerous growth. Techniques like gene editing, insertion of tumor-suppressor genes, and silencing of oncogenes are being explored to directly target cancer cells while sparing normal tissues, improving treatment efficacy and reducing side effects [3, 4].

Several gene therapy techniques have emerged in oncology. One of the most well-known is CAR T-cell therapy, where a patient's T-cells are genetically modified to recognize and attack cancer cells. Another approach is oncolytic virotherapy, which uses genetically engineered viruses to infect and destroy cancer cells while stimulating an immune response. Researchers are also investigating the use of gene editing tools like CRISPR to directly correct cancer-causing mutations within tumor cells. These innovative therapies are showing great promise in clinical trials for various types of cancer, including leukemia, melanoma, and lung cancer [5, 6].

Despite its potential, gene therapy in oncology is not without challenges. The human genome is complex, and making precise genetic modifications can be difficult. Off-target effects, where unintended parts of the genome are altered, pose a significant risk. Additionally, the high cost of developing gene therapies and ensuring their accessibility to patients remains a concern. Ethical issues surrounding the manipulation of genetic material also arise, particularly regarding long-term effects and the possibility of unintended consequences [7, 8 ].

The future of gene therapy in oncology is bright, with ongoing research focused on improving the precision, safety, and affordability of these treatments. Personalized medicine, where gene therapy is tailored to the individual’s unique genetic profile, is becoming a reality, offering hope for more effective and less invasive cancer treatments. As our understanding of cancer biology and genetics deepens, gene therapy could become a cornerstone in the fight against cancer, potentially offering cures for cancers that were once deemed untreatable [9, 10].

Conclusion

Gene therapy represents a groundbreaking shift in the field of oncology, providing new avenues for treating cancer at the genetic level. While challenges remain in ensuring the safety and accessibility of these treatments, the potential benefits for cancer patients are immense. As research continues to advance, gene therapy could transform the future of cancer care, offering more targeted, effective, and personalized treatments for this complex and deadly disease.

References

1. Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sci. 2021;269:119087.

Indexed at, Google Scholar, Cross Ref

2. Sheikh-Hosseini M, Larijani B, Gholipoor Kakroodi Z, et al. Gene therapy as an emerging therapeutic approach to breast cancer: new developments and challenges. Human Gene Ther. 2021;32(21-22):1330-45.

Indexed at, Google Scholar, Cross Ref

3. Gustafson MP, Ligon JA, Bersenev A, et al. Emerging frontiers in immuno-and gene therapy for cancer. Cytotherapy. 2023;25(1):20-32.

Indexed at, Google Scholar, Cross Ref

4. Kobelt D, Pahle J, Walther W. A brief introduction to current cancer gene therapy.Gene Ther Canc Method Protoc. 2022.

Indexed at, Google Scholar, Cross Ref

5. Patel MP, Shah MS, Athalye MN, et al. Gene therapy for cancer treatment: recent trends and clinical evidence. Gene Deliv Sys. 2022:163-80.

Indexed at, Google Scholar, Cross Ref

6. Bezeljak U. Cancer gene therapy goes viral: Viral vector platforms come of age. Radiol Oncolo. 2022;56(1):1-3.

Indexed at, Google Scholar, Cross Ref

7. Younis MA, Khalil IA, Harashima H. Gene therapy for hepatocellular carcinoma: Highlighting the journey from theory to clinical applications. Advan Therap. 2020;3(11):2000087.

Indexed at, Google Scholar, Cross Ref

8. Ou X, Ma Q, Yin W, et al. CRISPR/Cas9 gene-editing in cancer immunotherapy: Promoting the present revolution in cancer therapy and exploring more. Fronti Cell Developm Biolo. 2021;9:674467.

Indexed at, Google Scholar, Cross Ref

9. Shchaslyvyi AY, Antonenko SV, Tesliuk MG, et al. Current state of human gene therapy: Approved products and vectors. Pharmace. 2023;16(10):1416.

Indexed at, Google Scholar, Cross Ref

10. Zittersteijn HA, Gonçalves MA, Hoeben RC. A primer to gene therapy: Progress, prospects, and problems. J Inher Metabo Dise. 2021;44(1):54-71.

Indexed at, Google Scholar, Cross Ref